Nolato AB (publ) (NOLA_B) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's broadcast with Olato, who will be presenting their financial report for the second quarter of 2026. With us, we have the CEO, Christer Wallqvist, and CFO, Per-Ola Holmström. If you wish to ask questions, you can do so via the form found to the right of the broadcast, and if you're calling and would like to ask a question, press star 9 to raise your hand and star 6 to activate your audio once you've been given the word. With that said, I hand it over to you, Christian Perola. The floor is yours. Thank you and welcome to the presentation of the second quarter for Nolato Group. Starting on page two, we saw a quarter with growth in both business areas with a total growth of 4% currency adjusted with the strongest growth in the medical business area. This was achieved in a difficult environment, I would say. So sales ended up at close to 2.5 billions in the quarter, and that was then 4% adjusted currency growth. The profit EBITDA ended up at 247 millions, creating a margin of 10.1%. The margin was affected by increased raw material prices and some startup costs for new programs. strong cash flow in the in the quarter ended up at 287 millions and as a total we have a very strong financial position enabling us to deliver on the intensified acquisition strategy as communicated previously turning to page three summing up the group so nolato consists of two business areas that create synergies across Both business areas are then working as a development and production partner for leading global customers. On page four, we see a summary of medical solutions development over the last 20 years. So we have seen a continuous sustainable growth and built a global expansion. On page 5, we see a summary of our focus product areas and as mentioned previousl...